拨康视云-B(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02592 拨康视云-B

未开盘 06-11 15:53:30

1.330

+0.080

+6.40%

最高1.340	最低1.250	成交量38.85万
今开1.250	昨收1.250	日振幅7.20%
总市值11.41亿	流通市值11.41亿	总股本8.58亿
成交额50.76万	换手率0.05%	流通股本8.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"拨康视云-B","latestPrice":1.33,"timestamp":1781164410559,"preClose":1.25,"halted":0,"volume":388500,"delay":0,"changeRate":0.06400000000000006,"floatShares":858000000,"shares":858000000,"eps":-0.103023,"marketStatus":"未开盘","change":0.08,"latestTime":"06-11 15:53:30","open":1.25,"high":1.34,"low":1.25,"amount":507615,"amplitude":0.072,"askPrice":1.33,"askSize":4000,"bidPrice":1.29,"bidSize":1500,"shortable":0,"etf":0,"ttmEps":-0.614,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781227800000},"marketStatusCode":0,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":1.25,"openAndCloseTimeList":[[1781141400000,1781150400000],[1781154000000,1781164800000]],"volumeRatio":2.423580784816678,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02592","defaultTab":"news","newsList":[{"id":"1159102593","title":"拨康视云-B6月9日配发571.2万股新股 占已发行股本约0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159102593","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159102593?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:42","pubTimestamp":1780994522,"startTime":"0","endTime":"0","summary":"拨康视云-B（股票代码：02592）于2026年6月9日发布公告称，公司根据2023年股权激励计划于当日配发并发行571.2万股普通股，占此前公司已发行股本（不含库藏股）约0.67%。\n公告显示，本次新股发行每股发行价为0港元。本次发行完成后，公司已发行股本由原先的851,907,081股增加至857,619,081股，库藏股数目维持为0股。\n公司于公告中确认，此次股票发行已获董事会正式授权并遵照相关上市规则及法律法规的规定进行。公告由公司秘书冯雅芳签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"拨康视云-B6月9日配发571.2万股新股 占已发行股本约0.67%","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642463848","title":"拨康视云-B(02592)根据股权激励计划发行571.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642463848","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642463848?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:36","pubTimestamp":1780994200,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B(02592)发布公告，于2026年6月9日，根据2023年股权激励计划配发及发行571.2万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138416578","title":"拨康视云宣布翼状胬肉潜在疗法CBT-001三期研究完成12个月疗效终点最终患者访视","url":"https://stock-news.laohu8.com/highlight/detail?id=1138416578","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138416578?lang=zh_cn&edition=full","pubTime":"2026-06-05 05:01","pubTimestamp":1780606896,"startTime":"0","endTime":"0","summary":"拨康视云（Cloudbreak Pharma）近日宣布，其针对翼状胬肉潜在治疗药物CBT-001开展的三期临床研究，已完成12个月疗效终点的最终患者访视。这一关键里程碑标志着该试验在评估长期治疗效果方面取得了实质性进展，为后续数据分析及监管申报奠定了重要基础。公司将持续推进研究进程，致力于为这一常见眼表疾病提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640864150","title":"拨康视云-B：核心产品CBT-001临床试验达重要里程碑，有望成全球首个翼状胬肉治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2640864150","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640864150?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:28","pubTimestamp":1780576080,"startTime":"0","endTime":"0","summary":"6月4日，拨康视云-B（02592）发布公告，其核心产品CBT-001的最后一名患者已完成为期12个月的终点访视，并于此次访视中进行了对CBT-001主要疗效终点（翼状胬肉病变缩小程度及眼部不适症状评分）在第3期多地区临床试验（“多地区临床试验”）中的评估。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760601811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK4090","02592","CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640161151","title":"拨康视云-B(02592)完成CBT-001最后一次为期12个月的终点访视","url":"https://stock-news.laohu8.com/highlight/detail?id=2640161151","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640161151?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:49","pubTimestamp":1780570172,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B 发布公告，最后一名患者已完成为期12个月的访视，并于此次访视中进行了对CBT-001主要疗效终点在第3期多地区临床试验中的评估。CBT-001为本集团核心产品之一。CBT-001又称尼达尼布游离硷，是一种局部眼用滴眼液乳液，目前正进行第3期多地区临床试验研究。本公司认为，完成最后一次为期12个月的终点访视是CBT-001开发过程中的重要里程碑，此举将使本公司得以在2026年第三季度公布12个月疗效的初步数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4090","BK1161","02592","CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113341406","title":"拨康视云-B 5月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1113341406","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113341406?lang=zh_cn&edition=full","pubTime":"2026-06-01 10:25","pubTimestamp":1780280745,"startTime":"0","endTime":"0","summary":"根据拨康视云-B于2026年6月1日提交的截至2026年5月31日的月报表显示，公司本期注册股本总额保持在2,000,000,000股普通股，面值为每股USD 0.0001，总额USD 200,000。已发行股份数量期初为851,907,081股，期末亦为851,907,081股，未发生新增发行、购回或注销。公司确认已遵守香港联交所《上市规则》及相关法律规定，所有股份及潜在股份的发行、回购及注销均得到了公司董事会正式批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136526263","title":"拨康视云向FDA提交CBT-358新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1136526263","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136526263?lang=zh_cn&edition=full","pubTime":"2026-05-22 23:27","pubTimestamp":1779463662,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc.已向美国食品药品监督管理局提交了其候选药物CBT-358的研究性新药申请。此举标志着该药物向进入临床试验阶段迈出了关键一步。\n公司股票代码为2592.HK。相关信息发布后，市场将密切关注后续进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111758029","title":"拨康视云-B授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1111758029","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111758029?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:46","pubTimestamp":1779461217,"startTime":"0","endTime":"0","summary":"拨康视云制药有限公司发布公告称，董事会将于2026年6月26日召开的股东周年大会上，提请股东批准一项股份购回授权，规模最高可达已发行股本的10%。公告显示，截至2026年5月18日，公司已发行股份总数约为851,907,081股，若本次购回授权获批，最多可回购约85,190,708股股份。根据公告，若获准购回的股份日后作为库存股份持有，公司在符合监管要求的前提下，有可能进行转售或用于其他合理目的。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"拨康视云-B授予董事股份购回授权，规模达已发行股本一成","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637348383","title":"拨康视云-B(02592)：就CBT-358提交新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2637348383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637348383?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:37","pubTimestamp":1779460627,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B 发布公告，于2026年5月21日，集团向美国食品及药物管理局提交有关CBT-358的新药临床试验申请。因此，CBT-358 有可能同时解决水液缺乏型及过度蒸发型干眼症，两者为多数干眼症的根本成因。基于该项极具前景的突破，该公司已加速 CBT-358 的开发进程，并较预期更早地成功完成支持新药临床试验申请的研究。提交新药临床试验申请为美国药管局启动药物审查程序以及取得监管批准以展开CBT-358的临床试验的第一步。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CBT","BK1161","02592","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121293083","title":"拨康视云-B更新2026年4月股份变动月报表，股本略有增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1121293083","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121293083?lang=zh_cn&edition=full","pubTime":"2026-05-04 10:01","pubTimestamp":1777860108,"startTime":"0","endTime":"0","summary":"拨康视云-B于2026年5月4日发布2026年4月股份变动月报表，报告期为2026年4月1日至2026年4月30日。公告显示，公司注册股本维持2,000,000,000股普通股，面值每股0.0001美元，注册股本总额200,000美元，与上月无变化。报告指出，系列C股权激励安排下的13,082,881份受限制股份单元已于本月注销；系列C股权激励安排的购股权及其他股权激励计划未有行使增加已发行股份的记录。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631686436","title":"拨康视云-B(02592)：美国药管局已完成对CBT-199的安全性审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2631686436","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631686436?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:41","pubTimestamp":1777538474,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B 发布公告，本公司于美利坚合众国(美国)特拉华州注册成立的全资附属公司 ADS Therapeutics LLC ，已完成有关于2025年12月12日向美国食品及药物管理局提交的CBT-199新药临床试验申请的审查期。美国药管局已完成对新药临床试验申请的安全性审查，而美国药管局的结论为本公司可推进拟议的临床研究。本公司认为，由于美国药管局已完成对CBT-199的安全性审查，标志着CBT-199临床开发的关键里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CBT","BK4090","02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1107086204","title":"拨康视云-B新药CBT-199获FDA安全审查通过 临床试验获准推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1107086204","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107086204?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:38","pubTimestamp":1777538296,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已完成对拨康视云-B旗下创新药物CBT-199的新药临床试验申请（IND）的安全性评估。此次审查的顺利通过，意味着该药物已获准进入下一阶段的临床研究。\n此次安全审查的通过为CBT-199的临床开发路径清除了关键监管障碍。根据流程，制药企业可在获得FDA安全性认可后，正式启动针对候选药物的临床阶段研究。\n这一进展标志着拨康视云-B在创新药研发领域迈出重要一步。随着临床试验的推进，CBT-199的治疗潜力将得到进一步验证，为后续研发工作奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124358329","title":"拨康视云-B（02592）完成基金赎回 48.0百万港元到账，年化回报约2.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124358329","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124358329?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:46","pubTimestamp":1776861971,"startTime":"0","endTime":"0","summary":"拨康视云-B4月22日披露，已按董事会决议完成此前所持基金的全部赎回。公司共收回赎回款项约48.0百万港元，并实现收益约0.88百万港元，对应年化回报率约2.53%。\\n\\n此次赎回旨在降低不合规影响，保证所得款项用途符合规定。该基金注册于开曼群岛，为受当地金融管理局监管的豁免有限公司，资产管理规模逾1亿美元，持有人超过10名，且无单一投资者持股超过10%。基金普通合伙人的董事兼最终实益拥有人为Saadeddine Hanane，其与拨康视云-B及其关联方均保持独立。\\n\\n截至公告日，拨康视云-B董事会由3名执行董事、3名非执行董事及3名独立非执行董事组成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107056212","title":"拨康视云-B全额赎回基金，获资4800万港元，录得88万港元收益，年化回报率达2.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107056212","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107056212?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:43","pubTimestamp":1776861795,"startTime":"0","endTime":"0","summary":"拨康视云-B宣布完成基金全额赎回操作，成功收回4800万港元资金。本次赎回为集团带来88万港元的投资收益，经计算年化回报率达到2.53%。此次交易体现了公司资金管理的高效运作，为股东创造了稳健的价值回报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625193462","title":"拨康视云-B(02592)发行178.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625193462","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625193462?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:35","pubTimestamp":1775558156,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B(02592)发布公告，于2026年4月3日，根据2023年股权激励计划配发及发行178.5万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164294550","title":"拨康视云-B：4月3日配发发行178.50万股股份，占已发行股本0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164294550","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164294550?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:12","pubTimestamp":1775556760,"startTime":"0","endTime":"0","summary":"拨康视云-B(股票代码：02592)于2026年4月7日发布公告，披露公司在2026年4月3日根据2023年股权激励计划配发及发行178.50万股普通股，占发行前已发行股本850,122,081股的约0.21%。每股发售价为0港元。上述发行完成后，公司已发行股本增至851,907,081股，库藏股数量维持为0股。\n公告同时确认，本次股份发行已获董事会正式授权并遵守香港联合交易所有限公司证券上市规则及相关法律程序。公告由公司秘书冯雅芳签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176722646","title":"拨康视云-B3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1176722646","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176722646?lang=zh_cn&edition=full","pubTime":"2026-04-01 12:21","pubTimestamp":1775017268,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc.于2026年4月1日发布截至2026年3月31日的股份变动月报表。公告显示，公司3月期间未有新增发行、购回或注销股份，整体股本维持稳定。截至3月31日，公司实际已发行股份合计850,122,081股，与上月期末持平，库藏股份为0股。公司在公告中声明，所有股份和激励计划均已获得董事会正式授权，并遵守香港联交所《上市规则》及相关法律规定。至此，公司本月股本结构未发生实质性变化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623328973","title":"拨康视云-B(02592)发布年度业绩 净亏损6766万美元 同比收窄31.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623328973","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623328973?lang=zh_cn&edition=full","pubTime":"2026-03-31 01:39","pubTimestamp":1774892378,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B(02592)发布截至2025年12月31日止年度年度业绩，该集团研发开支6680.2万美元，同比扩大76.04%;净亏损6766万美元，同比收窄31.75%;每股基本亏损0.10美元。公告称，待监管机构批准后，我们预计将在约四年内(即2030年前)于美国市场推出CBT-001。同时，我们将评估商业化方案，同时最大限度地发挥我们专有技术及资产，作为我们投资组合的一部分。鉴于翼状胬肉及结膜充血患者数目众多，且市场竞争有限，我们预期CBT-001上市后将有巨大市场机会及可观收益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"拨康视云-B(02592)发布年度业绩 净亏损6766万美元 同比收窄31.75%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620420690","title":"港股异动 | 拨康视云-B(02592)跌超6%创新低 宣布撤回CBT-009新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420690","media":"智通财经","labels":["executive","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620420690?lang=zh_cn&edition=full","pubTime":"2026-03-20 10:35","pubTimestamp":1773974109,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，拨康视云-B跌超6%，低见1.82港元刷新上市以来新低。在提交新药临床试验申请后，药审中心批准了一款可比药品在中国上市。经后续与药审中心沟通后，公司相信由于各区域监管要求不同，将中国纳入多地区临床试验可能存在困难。为避免后续研发风险，及更好地分配集团的资源，公司已决定主动就可能于中国进行的第三期试验撤回现有的新药临床试验申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK4588","CBT","BK1161","BK4090","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244220","title":"拨康视云-B(02592)：撤回CBT-009新药临床试验申请 重新评估临床开发策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244220","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620244220?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:05","pubTimestamp":1773918320,"startTime":"0","endTime":"0","summary":"在提交新药临床试验申请后，药审中心批准了一款可比药品在中国上市。经后续与药审中心沟通后，公司相信由于各区域监管要求不同，将中国纳入多地区临床试验可能存在困难。为避免后续研发风险，及更好地分配集团的资源，公司已决定主动就可能于中国进行的第三期试验撤回现有的新药临床试验申请。待完成相关补充研究或调整临床试验方案后，公司将根据情况再次与药审中心进行临床试验申请前咨询会议或重新提交临床试验申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","CBT","BK1161","BK4090"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://cloudbreakpharma.com","stockEarnings":[{"period":"1week","weight":0.1271},{"period":"1month","weight":-0.0567},{"period":"3month","weight":-0.3512},{"period":"6month","weight":-0.8092},{"period":"1year","weight":-0.8683},{"period":"ytd","weight":-0.7442}],"compareEarnings":[{"period":"1week","weight":-0.0398},{"period":"1month","weight":-0.0797},{"period":"3month","weight":-0.0478},{"period":"6month","weight":-0.0665},{"period":"1year","weight":-0.0048},{"period":"ytd","weight":-0.0539}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"Cloudbreak Pharma Inc是一家临床阶段的眼科生物技术公司，从事开发各种治疗方法。该公司专注于眼科疗法的内部发现、开发和商业化。该公司拥有两款核心产品 CBT-001和CBT-009，均为自主研发。该公司的核心产品CBT-001用于治疗翼状胬肉（一种良性增生性眼表疾病），已在美国和中国启动III期多区域临床试验（MRCT）。该公司的核心产品CBT-009用于治疗青少年近视（5至19岁儿童和青少年的近视），已完成I/II期临床试验。该公司的其他候选药物处于相对早期的开发阶段，包括另外两种临床阶段候选药物，即CBT-006和CBT-004，以及四种临床前阶段候选药物，即CBT-007、CBT-199、CBT-145和CBT-011。","exchange":"SEHK","name":"拨康视云-B","nameEN":"CLOUDBREAK-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拨康视云-B(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拨康视云-B(02592)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拨康视云-B,02592,拨康视云-B股票,拨康视云-B股票老虎,拨康视云-B股票老虎国际,拨康视云-B行情,拨康视云-B股票行情,拨康视云-B股价,拨康视云-B股市,拨康视云-B股票价格,拨康视云-B股票交易,拨康视云-B股票购买,拨康视云-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拨康视云-B(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拨康视云-B(02592)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}